Loading...

Alder BioPharmaceuticals

DB:3A9
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3A9
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
3A9 Share Price and Events
7 Day Returns
-3.5%
DB:3A9
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
0.3%
DB:3A9
-10.2%
DE Biotechs
-6%
DE Market
3A9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alder BioPharmaceuticals (3A9) -3.5% -10.4% -2.6% 0.3% -56.5% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 3A9 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 3A9 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
3A9
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Alder BioPharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Alder BioPharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Alder BioPharmaceuticals.

DB:3A9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:3A9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (17.27%))
1.432
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.43
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.432 * 5.96%)
8.76%

Discounted Cash Flow Calculation for DB:3A9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Alder BioPharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:3A9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.76%)
2019 -300.50 Analyst x5 -276.28
2020 -182.25 Analyst x4 -154.06
2021 -52.50 Analyst x3 -40.80
2022 73.19 Analyst x2 52.30
2023 226.60 Analyst x2 148.88
2024 387.37 Est @ 70.95% 233.99
2025 580.01 Est @ 49.73% 322.12
2026 782.32 Est @ 34.88% 399.47
2027 973.88 Est @ 24.48% 457.21
2028 1,141.46 Est @ 17.21% 492.70
Present value of next 10 years cash flows $1,635.52
DB:3A9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,141.46 × (1 + 0.23%) ÷ (8.76% – 0.23%)
$13,401.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $13,401.83 ÷ (1 + 8.76%)10
$5,784.80
DB:3A9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,635.52 + $5,784.80
$7,420.32
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,420.32 / 83.15
$89.24
DB:3A9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:3A9 represents 0.86834x of NasdaqGM:ALDR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86834x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 89.24 x 0.86834
€77.49
Value per share (EUR) From above. €77.49
Current discount Discount to share price of €11.08
= -1 x (€11.08 - €77.49) / €77.49
85.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Alder BioPharmaceuticals is available for.
Intrinsic value
>50%
Share price is €11.08 vs Future cash flow value of €77.49
Current Discount Checks
For Alder BioPharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Alder BioPharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Alder BioPharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alder BioPharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alder BioPharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3A9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.87
NasdaqGM:ALDR Share Price ** NasdaqGM (2019-04-18) in USD $12.76
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alder BioPharmaceuticals.

DB:3A9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALDR Share Price ÷ EPS (both in USD)

= 12.76 ÷ -4.87

-2.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alder BioPharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alder BioPharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alder BioPharmaceuticals's expected growth come at a high price?
Raw Data
DB:3A9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
45.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alder BioPharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alder BioPharmaceuticals's assets?
Raw Data
DB:3A9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.61
NasdaqGM:ALDR Share Price * NasdaqGM (2019-04-18) in USD $12.76
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:3A9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALDR Share Price ÷ Book Value per Share (both in USD)

= 12.76 ÷ 1.61

7.94x

* Primary Listing of Alder BioPharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alder BioPharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alder BioPharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alder BioPharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Alder BioPharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
45.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alder BioPharmaceuticals expected to grow at an attractive rate?
  • Alder BioPharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Alder BioPharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Alder BioPharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:3A9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3A9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 45.9%
DB:3A9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 62.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3A9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3A9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 519 115 122 7
2022-12-31 368 69 59 8
2021-12-31 184 -94 -127 10
2020-12-31 62 -214 -248 14
2019-12-31 7 -277 -312 13
DB:3A9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -251 -332
2018-09-30 1 -234 -305
2018-06-30 1 -227 -302
2018-03-31 2 -239 -306
2017-12-31 2 -227 -289
2017-09-30 1 -223 -283
2017-06-30 1 -222 -259
2017-03-31 0 -194 -223
2016-12-31 0 -160 -156
2016-09-30 0 -135 -134
2016-06-30 0 -111 -125
2016-03-31 -92 -104

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alder BioPharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Alder BioPharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3A9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Alder BioPharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3A9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.34 1.70 1.10 4.00
2022-12-31 0.92 1.58 0.44 3.00
2021-12-31 -1.47 -0.30 -2.42 9.00
2020-12-31 -3.13 -1.75 -4.08 12.00
2019-12-31 -4.30 -3.00 -4.99 13.00
DB:3A9 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.87
2018-09-30 -4.48
2018-06-30 -4.50
2018-03-31 -4.88
2017-12-31 -4.95
2017-09-30 -5.25
2017-06-30 -5.14
2017-03-31 -4.46
2016-12-31 -3.23
2016-09-30 -2.86
2016-06-30 -2.78
2016-03-31 -2.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alder BioPharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Alder BioPharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alder BioPharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Alder BioPharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alder BioPharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alder BioPharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alder BioPharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alder BioPharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alder BioPharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alder BioPharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3A9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -331.93 47.47 77.11
2018-09-30 0.94 -304.82 44.84 74.20
2018-06-30 0.94 -302.19 42.39 71.09
2018-03-31 1.62 -306.13 39.78 66.46
2017-12-31 1.62 -288.88 38.10 64.22
2017-09-30 0.68 -283.41 35.16 60.44
2017-06-30 0.68 -258.98 33.17 55.62
2017-03-31 0.11 -223.22 30.08 50.23
2016-12-31 0.11 -156.25 26.15 44.41
2016-09-30 0.11 -133.53 23.54 38.53
2016-06-30 0.11 -125.39 21.62 34.48
2016-03-31 -104.18 19.09 30.23
2015-12-31 -85.47 16.72 26.58
2015-09-30 6.44 -66.25 15.33 23.65
2015-06-30 45.22 -10.60 14.17 21.09
2015-03-31 49.92 -0.35 12.98 19.52
2014-12-31 54.71 8.91 12.46 18.30
2014-09-30 53.09 11.98 11.41 17.84
2014-06-30 19.02 -22.58 10.11 18.00
2014-03-31 18.98 -20.33 9.01 18.25
2013-12-31 18.80 -20.61 7.67 18.77
2013-09-30 18.75 -20.81 7.34 19.24
2012-12-31 20.07 -17.81 7.22 19.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alder BioPharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alder BioPharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alder BioPharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alder BioPharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alder BioPharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Alder BioPharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alder BioPharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alder BioPharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alder BioPharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alder BioPharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alder BioPharmaceuticals Company Filings, last reported 3 months ago.

DB:3A9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 213.73 182.10 407.37
2018-09-30 285.13 179.04 452.41
2018-06-30 340.76 176.05 308.56
2018-03-31 400.11 173.20 330.96
2017-12-31 279.28 0.00 276.24
2017-09-30 327.17 0.00 330.89
2017-06-30 219.42 0.00 224.48
2017-03-31 287.76 0.00 289.56
2016-12-31 382.78 0.00 351.87
2016-09-30 426.74 0.00 403.39
2016-06-30 458.07 0.00 447.35
2016-03-31 357.65 0.00 303.15
2015-12-31 387.52 0.00 305.17
2015-09-30 411.67 0.00 306.18
2015-06-30 436.67 0.00 428.41
2015-03-31 236.17 0.00 230.26
2014-12-31 59.16 0.00 55.87
2014-09-30 64.91 0.00 66.61
2014-06-30 35.88 0.00 77.59
2014-03-31 -37.19 0.00 12.94
2013-12-31 -31.99 0.00 23.23
2013-09-30 -28.30 0.00 31.40
2012-12-31 -12.01 0.00 59.37
  • Alder BioPharmaceuticals's level of debt (85.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 85.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alder BioPharmaceuticals has sufficient cash runway for 1.6 years based on current free cash flow.
  • Alder BioPharmaceuticals has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 30.9% each year.
X
Financial health checks
We assess Alder BioPharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alder BioPharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Alder BioPharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alder BioPharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Alder BioPharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alder BioPharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alder BioPharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3A9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3A9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alder BioPharmaceuticals has not reported any payouts.
  • Unable to verify if Alder BioPharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alder BioPharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alder BioPharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alder BioPharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alder BioPharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alder BioPharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alder BioPharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Alder BioPharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Azelby
AGE 50
TENURE AS CEO 0.8 years
CEO Bio

Mr. Robert W. Azelby, also known as Bob, M.B.A. has been Director of Clovis Oncology, Inc since October 11, 2018. He serves as Chief Executive Officer, President and Director of Alder Bio Pharmaceuticals, Inc. since June 13, 2018. Mr. Azelby served as Chief Commercial Officer and Executive Vice President of Juno Therapeutics Inc. since November 2, 2015 to May 2018. Prior to joining Juno in 2015, Mr. Azelby served as Vice President of Amgen’s North American Commercial Effectiveness Unit and was responsible for sales and marketing functions, including market research, forecasting, sales training and sales operations. Mr. Azelby worked at Amgen Inc. where he served as Vice President and General Manager of Amgen’s Oncology Business Unit From June 2012 to October 2015. He joined Amgen Inc. in 2000. During his 15 year tenure at Amgen, he served as Vice President of Amgen’s U.S. Oncology Sales team, which was one of the largest oncology sales teams in the U.S. He garnered international experience as Amgen’s General Manager, Netherlands, responsible for all aspects of its commercial operations in that country From June 2012 to October 2015. Mr. Azelby has over 26 years of biopharmaceutical industry expertise. He held numerous sales and marketing positions, each with increasing responsibilities. His roles included project management, business development, regional sales management and national marketing director. Mr. Azelby began his career in the industry as a sales representative in Philadelphia for the former British drug company Glaxo Welcome PLC. He then worked for Oxford Health Plans, a subsidiary of the healthcare organization Oxford Health, and the medical risk management start-up Avandel Inc. before joining Amgen. He has been Director of Alliance for Regenerative Medicine since 2018. He served as a Director of Cascadian Therapeutics, Inc. from April 2017 to March 9, 2018. Mr. Azelby is a biotechnology and pharmaceutical industry veteran. Mr. Azelby received his Bachelor’s Degree(B.A) in Economics and Religious Studies from University of Virginia and his Master of Business Administration from Harvard University.

CEO Compensation
  • Insufficient data for Bob to compare compensation growth.
  • Insufficient data for Bob to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alder BioPharmaceuticals management team in years:

2.2
Average Tenure
55.5
Average Age
  • The tenure for the Alder BioPharmaceuticals management team is about average.
Management Team

John Latham

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$2M
AGE
58
TENURE
15.3 yrs

Larry Benedict

TITLE
Principal Accounting Officer & Executive VP
COMPENSATION
$1M
AGE
57
TENURE
2.5 yrs

Jeffrey T. Smith

TITLE
Managing Director of Alder Biopharmaceuticals Limited
COMPENSATION
$2M
AGE
58
TENURE
2.1 yrs

Bob Azelby

TITLE
President
AGE
50
TENURE
0.8 yrs

Carlos Campoy

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Erin Lavelle

TITLE
Chief Operating Officer
AGE
40
TENURE
1 yrs

James Bucher

TITLE
Executive VP & General Counsel
AGE
52
TENURE
3.3 yrs

Randy Hassler

TITLE
Executive Senior Vice President of Pharmaceutical Operations
AGE
61
TENURE
4.7 yrs

Annette Vahratian

TITLE
Senior Vice President of Quality
TENURE
2.3 yrs

Paul Streck

TITLE
Chief Medical Officer
AGE
54
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Alder BioPharmaceuticals board of directors in years:

9.9
Average Tenure
57
Average Age
  • The tenure for the Alder BioPharmaceuticals board of directors is about average.
Board of Directors

Paul Cleveland

TITLE
Chairman of the Board
COMPENSATION
$199K
AGE
61

Bob Azelby

TITLE
President
AGE
50
TENURE
0.8 yrs

Clay Siegall

TITLE
Director
COMPENSATION
$191K
AGE
57
TENURE
13.4 yrs

Wendy Yarno

TITLE
Director
COMPENSATION
$514K
AGE
63
TENURE
2.1 yrs

Heather Preston

TITLE
Director
COMPENSATION
$192K
AGE
52
TENURE
11.3 yrs

Deepa Pakianathan

TITLE
Director
COMPENSATION
$186K
AGE
53
TENURE
11.3 yrs

Alan Montgomery

TITLE
Director
COMPENSATION
$184K
AGE
65
TENURE
8.5 yrs

Peter Goadsby

TITLE
Scientific Advisor

David Dodick

TITLE
Member of Advisory Board

Richard Lipton

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Alder BioPharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alder BioPharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company’s lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Details
Name: Alder BioPharmaceuticals, Inc.
3A9
Exchange: DB
Founded: 2002
$936,463,253
83,149,706
Website: http://www.alderbio.com
Address: Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South,
Bothell,
Washington, 98011,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALDR Common Stock Nasdaq Global Market US USD 08. May 2014
DB 3A9 Common Stock Deutsche Boerse AG DE EUR 08. May 2014
Number of employees
Current staff
Staff numbers
202
Alder BioPharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:08
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.